Novo Nordisk Seeking to Expand Weight-Loss Drugs Access in Japan
Novo Nordisk A/S is seeking to broaden access to obesity treatments in Japan by targeting patients willing to pay out-of-pocket for GLP-1 drugs such as Wegovy.
By Kanoko Matsuyama ยท Bloomberg
Novo Nordisk A/S is seeking to broaden access to obesity treatments in Japan by targeting patients willing to pay out-of-pocket for GLP-1 drugs such as Wegovy.